Apyx Medical (APYX) has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company’s common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company’s common stock at a purchase price of $1.179 per pre-funded warrant. The gross proceeds to Apyx Medical from the offering were approximately $7,000,000, before deducting offering expenses payable by the Company. The offering closed on November 8, 2024. The purchase price of $1.18 per share of common stock was calculated using the average closing price of the Company’s common stock on the Nasdaq Global Select Market for the five trading days prior to market close on November 7, 2024. The Company did not use a placement agent in connection with the offering. Apyx Medical intends to use the proceeds from the offering for working capital and other general corporate purposes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APYX:
- Apyx Medical reports Q3 EPS (14c), consensus (19c)
- Apyx Medical cuts FY24 revenue view to $46.6M-$47.6M from $50.6M-$52.1M
- Apyx Medical sees FY25 revenue view to $47.6M-$49.5M, consensus $54.04M
- APYX Upcoming Earnings Report: What to Expect?
- Apyx Medical initiated with a Neutral at BTIG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
